Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.

Autor: Dingli D; Mayo Clinic, Rochester, MN, USA., De Castro Iii C; Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA., Koprivnikar J; Hackensack University Medical Center, Hackensack, NJ, USA., Kulasekararaj A; King's College Hospital and King's College London, London, England., Maciejewski J; Cleveland Clinic, Cleveland, OH, USA., Mulherin B; Hematology Oncology of Indiana, PC, American Oncology Network, Indianapolis, IN, USA., Panse J; RWTH Aachen University Hospital, Aachen, Germany + Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany., Pullarkat V; City of Hope, Duarte, CA, USA., Röth A; West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Shammo J; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Terriou L; University Hospital of Lille, Lille, France., Weitz I; Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA., Yermilov I; PHAR, Beverly Hills, CA, USA., Gibbs S; PHAR, Beverly Hills, CA, USA., Broder M; PHAR, Beverly Hills, CA, USA., Beenhouwer D; PHAR, Beverly Hills, CA, USA., Kuter D; Massachusetts General Hospital, Boston, MA, USA.

Publikováno v: Hematology (Amsterdam, Netherlands) [Hematology] 2024 Dec; Vol. 29 (1), pp. 2329030. Date of Electronic Publication: 2024 Mar 21.

Eculizumab: A Guide to its Use in Paroxysmal Nocturnal Hemoglobinuria.

Autor: Keating, Gillian M., Lyseng-Williamson, Katherine A., McKeage, Kate

Publikováno v: BioDrugs. 2012, Vol. 26 Issue 2, p125-130. 6p. 2 Charts, 1 Graph.